Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 weeks in daily practice

Clinical and Experimental Rheumatology

Volumn 26, Issue 2, 2008, Pages 247-252

  Haibel, Hildrun ^a   Song, In Ho ^a   Rudwaleit, Martin ^a   Listing, Joachim ^b   Hildemann, Steven ^c   Sieper, Joachim ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b German Rheumatism Research Centre   (Germany)

^c Essex Pharma   (Germany)

Author keywords

Ankylosing spondylitis; Daily practice; Infliximab; Open label trial

Indexed keywords

INFLIXIMAB;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; DIARRHEA; DISEASE ACTIVITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL STATUS; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; RHINOPHARYNGITIS; SHORT FORM 36; SIDE EFFECT; TOXIC HEPATITIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WORK CAPACITY;

ACTIVITIES OF DAILY LIVING; ACUTE DISEASE; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; EMPLOYMENT; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; PRIVATE PRACTICE; PROSPECTIVE STUDIES; QUALITY OF LIFE; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 43349087251     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. LEHTINEN K: Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 1993; 52: 174-6.
2. BRAUN J, PINCUS T: Mortality, course of disease and prognosis of patients with ankylosing spondylitis. Clin Exp Rheumatol 2002; 20 (Suppl. 28): S16-22.
3. BOONEN A: Socioeconomic consequences of ankylosing spondylitis. Clin Exp Rheumatol 2002; 20 (Suppl. 28): S23-6.
4. HAIBEL H, BRANDT HC, SONG IH et al.: No efficacy of subcutaneous methotrexate in active ankylosing spondylitis - a 16 weeks open label trial. Ann Rheum Dis 2007; 66: 419-21.
5. ZOCHLING J, VAN DER HEIJDE D, BURGOS-VARGAS R et al.: ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65: 442-52.
6. BRANDT J, KHARIOUZOV A, LISTING J et al.: Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003; 48: 1667-75.
7. BRAUN J, BRANDT J, LISTING J et al.:TReatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial. Lancet 2002; 359: 1187-93.
8. VAN DER HEIJDE D, KIVITZ A, SCHIFF MH et al.: Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 2136-46.
9. BRANDT J, HAIBEL H, CORNELY D et al.: Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000; 43: 1346-52.
10. VAN DER HEIJDE D, DIJKMANS B, GEUSENS P et al.: Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52: 582-91.
11. VAN DER LINDEN S, VALKENBURG HA, CATS A: Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8.
12. VAN DER HEIJDE D, CALIN A, DOUGADOS M, KHAN MA, VAN DER LINDEN S, BELLAMY N: Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. Assessments in Ankylosing Spondylitis. J Rheumatol 1999; 26: 951-4.
13. WARE JE JR, SHERBOURNE CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-83.
14. VAN DER HEIJDE D, BELLAMY N, CALIN A, DOUGADOS M, KHAN MA, VAN DER LINDEN S: Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol 1997; 24: 2225-9.
15. BRANDT J, LISTING J, SIEPER J, RUDWALEIT M, VAN DER HEIJDE D, BRAUN J: Development and preselection of criteria for short-term improvement after anti-TNFα therapy in ankylosing spondylitis. Ann Rheum Dis 2004; 63: 1438-44.
16. REILLY MC, ZBROZEK AS, DUKES EM: The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993; 4: 353-65.
17. BRAUN J, BRANDT J, LISTING J et al.: Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003; 48: 2224-33.
18. VAN DER HEIJDE D, DIJKMANS B, GEUSENS P et al.: Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a 24-week randomized, placebo-controlled trial (ASSERT). In: Annual meeting of the European League Against Rheumatism (EULAR); 2004; Berlin, Germany; 2004.
19. VAN DER HEIJDE D, LUO M, MATSUMOTO A et al.: Adalimumab Improves Health-Related Quality of Life in Patients with Active Ankylosing Spondylitis - The ATLAS Trial. In: ACR; 2005; San Diego: Arthritis Rheumatism; 2005. p. S211.
20. DAVIS JC, VAN DER HEIJDE D, DOUGADOS M, WOOLLEY JM: Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheum 2005; 53: 494-501.
21. BULLINGER MIK: SF-36 Fragebogen zum Gesundheitszustand. Göttingen: Hogrefe-Verlag; 1998.
22. BREBAN M, VIGNON E, CLAUDEPIERRE P et al.: Efficacy of infliximab in refractory ankylosing spondylitis: Results of a six-month open-label study. Rheumatology (Oxford) 2002; 41: 1280-5.
23. RUDWALEIT M, LISTING J, BRANDT J, BRAUN J, SIEPER J: Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004; 63: 665-70.
24. RUDWALEIT M, LISTING J, BRANDT J, BRAUN J, SIEPER J: Prediction of a major clinical response (BASDAI 50) to TNF-α blockers in ankylosing spondylitis. Ann Rheum Dis 2004; 63: 665-670.
25. WARD MM: Health-related quality of life in ankylosinA spondylitis: a survey of 175 patients. Arthritis Care Res 1999; 12: 247-55.
26. ANTONI C, MAINI RN, GRUNKE N: Cooperative on quality of life in rheumatic disease: Results of a survey among 6000 patients across 11 European countries. Arthritis Rheum 2002; 46 (Suppl. 9): S76.
27. MAU W, LISTING J, HUSCHER D, ZEIDLER H, ZINK A: Employment across chronic inflammatory rheumatic diseases and comparison with the general population. J Rheumatol 2005; 32: 721-8.
28. LISTING J, BRANDT J, RUDWALEIT M, ZINK A, SIEPER J, BRAUN J: Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis. Ann Rheum Dis 2004; 63: 1670-2.
29. HAIBEL H, RUDWALEIT M, BRANDT HC et al.: Adalimumab reduces spinal symptoms in active ankylosing spondylitis: Clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 2006; 54: 678-81.
30. BRAUN J, PHAM T, SIEPER J et al.: International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003; 62: 817-24.
31. KOBELT G, ANDLIN-SOBOCKI P, BROPHY S, JONSSON L, CALIN A, BRAUN J: The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). Rheumatology (Oxford) 2004; 43: 1158-66.
32. KOBELT G, ANDLIN-SOBOCKI P, MAKSYMOWYCH WP: The cost-effectiveness of infliximab (Remicade) in the treatment of ankylosing spondylitis in Canada. J Rheumatol 2006; 33: 732-40.